Orchard Therapeutics Valuation

Q: What is the Fair Price of ORTX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

ORTX ($16.7) is trading above our estimate of [[fair value]] ($5.18)

Is ORTX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ORTX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ORTX ($16.7) is trading above our estimate of fair value ($5.18)

Significantly Below Fair Value: ORTX is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ORTX?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for ORTX. This is calculated by dividing ORTX's market cap by their current preferred multiple.
What is ORTX's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	US$380.12m

ORTX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	13.9x
Enterprise Value/EBITDA	-3x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does ORTX's PS Ratio compare to its peers?

The above table shows the PS ratio for ORTX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	11.1x
ADAP Adaptimmune Therapeutics	1.8x	8.6%	US$239.9m
MRSN Mersana Therapeutics	7.7x	35.1%	US$238.6m
ACIU AC Immune	20x	41.0%	US$362.1m
FHTX Foghorn Therapeutics	15x	32.7%	US$515.7m
ORTX Orchard Therapeutics	17.4x	34.5%	US$380.1m

Price-To-Sales vs Peers: ORTX is good value based on its Price-To-Sales Ratio (17.4x) compared to the peer average (20.2x).

Price to Earnings Ratio vs Industry

How does ORTX's PE Ratio compare vs other companies in the US Biotechs Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	28.3%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	28.3%
	n/a	n/a	n/a

No more companies

Price-To-Sales vs Industry: ORTX is expensive based on its Price-To-Sales Ratio (17.4x) compared to the US Biotechs industry average (13.1x).

Price to Sales Ratio vs Fair Ratio

What is ORTX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ORTX PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	17.4x
Fair PS Ratio	0.2x

Price-To-Sales vs Fair Ratio: ORTX is expensive based on its Price-To-Sales Ratio (17.4x) compared to the estimated Fair Price-To-Sales Ratio (0.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.